Acceleron Pharma (XLRN) Tops Q1 EPS by 6c

Acceleron Pharma (NASDAQ: XLRN) reported Q1 EPS of ($0.58), $0.06 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.23 million versus the consensus estimate of $4.21 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c